Relafen 750, the novel compound of naproxen, represents an fascinating case from a biochemical pharmacy view. This process of action, primarily involving blocking of cyclooxygenase enzymes namely COX-1 and COX-2 – contributes to a decrease in prostaglandin creation. Considering our biochemical lens, the drug's effectiveness is strongly related to